sotio_BC.png
Oral Presentation of Interim Data from the AURELIO-03 Study of SOT101 at the 2022 ASCO Annual Meeting
April 27, 2022 10:00 ET | SOTIO Biotech
SOTIO will share interim safety and efficacy results from SOTIO’s AURELIO-03 study on Saturday, June 4AURELIO-03 is a Phase 1/1b dose escalation study of the interleukin-15 superagonist SOT101 as...
sotio_BC.png
SOTIO Initiates CLAUDIO-01 Trial with Antibody-Drug Conjugate SOT102 in Patients with Gastric and Pancreatic Cancer
April 26, 2022 08:00 ET | SOTIO Biotech
CLAUDIO-01 is the first-in-human trial of SOT102, a CLDN18.2 (Claudin 18.2) targeting antibody-drug conjugate (ADC)The trial will enroll up to 109 patients with gastric and pancreatic cancer PRAGUE,...
sotio_BC.png
Interim Data from the Phase 1/1b AURELIO-03 Trial of SOT101 Presented at the AACR 2022 Annual Meeting
April 12, 2022 15:30 ET | SOTIO Biotech
PRAGUE, Czech Republic and BASEL, Switzerland and CAMBRIDGE, Mass, April 12, 2022 (GLOBE NEWSWIRE) -- Interim Results of the Phase 1 AURELIO-03 study of SOT101 in combination with pembrolizumab...
sotio_BC.png
SOTIO Announces Oral and Multiple Poster Presentations on Key Clinical Programs at the American Association of Cancer Research Annual Meeting (AACR) 2022
March 16, 2022 08:00 ET | SOTIO Biotech
Oral presentation will focus on interim efficacy and safety data from the Phase 1/1b AURELIO-03 study of SOT101 in combination with pembrolizumabPoster presentations will feature preclinical data on...
sotio_BC.png
SOTIO Announces Clinical Collaboration with MSD to Evaluate IL-15 Superagonist, SOT101, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors
December 08, 2021 08:00 ET | SOTIO Biotech
The Phase 2 AURELIO-04 study is expected to enroll up to 300 patients across six different indicationsThe study will be conducted in the US and selected European countries and will begin in the first...
sotio_BC.png
SOTIO Secures €280m of Funding to Expand and Advance Clinical Pipeline
December 02, 2021 08:00 ET | SOTIO Biotech
PPF Group provides funding to advance SOTIO through key clinical milestonesProceeds shall be used to conduct two phase 2 studies with SOT101, including a checkpoint inhibitor combination trial Three...
sotio_BC.png
SOTIO Strengthens its Strategic Advisory Board with Esteemed Oncology Experts and Industry Veterans
November 18, 2021 08:00 ET | SOTIO Biotech
PRAGUE, Czech Republic, Nov. 18, 2021 (GLOBE NEWSWIRE) -- SOTIO Biotech, a clinical stage immune-oncology company owned by PPF Group, announced the addition of three world-renowned clinical oncology...
sotio_BC.png
SOTIO Expands its Antibody-Drug Conjugate Pipeline with Exclusive Collaboration and License Agreement with LegoChem Biosciences
November 16, 2021 08:00 ET | SOTIO Biotech
SOTIO Biotech licenses LegoChem Biosciences (LCB) technology for five new antibody-drug conjugate (ADC) programsRights to LCB’s ADC platform acquired for total of up to $1027.5 million payable based...
sotio_BC.png
SOT101 Shows Clinical Benefit in Patients with Advanced Solid Tumors
November 12, 2021 07:00 ET | SOTIO Biotech
Majority of patients receiving SOT101 (SO-C101) + pembrolizumab had confirmed clinical benefitClinical responses have been observed in patients progressing on previous anti-PD-1 treatmentSOT101...
sotio_BC.png
SOTIO to Present New Data from Phase 1 Study of IL-15 Superagonist, SOT101, at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
November 03, 2021 08:00 ET | Sotio
SOTIO will present three posters discussing data that highlight the encouraging safety and efficacy for SOT101 (SO-C101) as a monotherapy and in combination with pembrolizumab for the treatment of...